What changed from existing technology?
This study shows that the design of CAR-T cells affects how cancer cells become resistant to treatment by changing the CD19 protein.
This is the first study to directly compare how different CAR-T structures lead to CD19 loss in tumor cells, showing that the 4-1BB-based structure causes more resistance than the CD28-based one.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
r relapsed/refractory B-cell malignancies, yet ~50% of patients relapse after infusion. Clinical data suggest that tisa-cel treatment is associated with highe
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This finding could help in designing more effective CAR-T therapies by understanding how different structures affect resistance mechanisms.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.